Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis
Sign Up to like & getrecommendations! Published in 2018 at "Endocrine"
DOI: 10.1007/s12020-018-1699-9
Abstract: Denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor kappaB ligand (RANKL), is considered an efficient and safe treatment of postmenopausal osteoporosis [1]. Its main adverse effects, including osteonecrosis of the jaw,… read more here.
Keywords: postmenopausal osteoporosis; treatment; denosumab; leukopenia following ... See more keywords